Application of solamargine to preparation of antitumor drug sensitizer and antitumor combined drug

An anti-tumor drug, solanine technology, applied in the field of biomedicine, can solve problems such as injury, neurotoxicity, and side effects

Pending Publication Date: 2020-11-03
北京科途医学科技有限公司
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, cisplatin will also damage the normal cells of the human body during the treatment of tumors, which will be accompanied by toxic side effects such as nephrotoxicity, bone marrow toxicity, and neurotoxicity. In severe cases, the treatment may not be carried out normally.
At the same time, in the process of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] In this example, cisplatin-resistant lung cancer organoids were used to detect the sensitization effect of solanine on cisplatin.

[0059] Take cisplatin-resistant lung cancer organoids, add 500 μL TrypLE Express, and digest for 1 min. After the enzymatic hydrolysis, the hydrolyzed product was centrifuged at 400 rcf for 4 min to collect the precipitate. Add Advanced DMEM / F12 medium containing 10% low growth factor Matrigel to the collected precipitate to make a single cell suspension, so that the cell concentration is 3×10 5 individual / mL. The single cell suspension was inoculated into a 96-well plate with an inoculum volume of 250 μL per well. After inoculation, 40 μL of Advanced DMEM / F12 medium was added to each well to obtain a culture plate for testing.

[0060] Add solanine, cisplatin, and their combined drugs with different concentration gradients to the test culture plate, the amount of reagent added in each culture well is 10 μL, and each concentration of each...

Embodiment 2

[0067] In this example, human lung cancer cell lines NCI-H460 and NCI-H1299 were used to detect the sensitization effect of solanine on cisplatin.

[0068] Human lung cancer cell lines NCI-H460 and NCI-H1299 were taken respectively, and the ratio of 0.75×10 3 The inoculum amount of cells / well was inoculated in a 96-well culture plate, and then incubated at 37°C, 5% CO 2 cultured in an incubator for 24 h. After the cells adhered to the wall, the culture medium was removed to obtain test culture plates for the above two cell lines respectively.

[0069]Add solanine, cisplatin, and their combined drugs with different concentration gradients to the test culture plate, the amount of reagent added in each culture well is 10 μL, and each concentration of each group of drugs is repeated 6 times. hole. Another test culture plate was taken, and an equal amount of normal saline was used to replace the reagent in the test group as a control group. After the test group and the control ...

Embodiment 3

[0078] Cisplatin-resistant lung cancer PDX mice were injected with cisplatin at a concentration of 50 μM, solanine at a concentration of 3.3 μM, and a combination drug containing 50 μM cisplatin / 3.3 μM solanine, and each mouse was injected with 10 μL . After 14 days, the reduction rate of the tumor volume of the PDX mice was observed, and the survival rate of the PDX mice was calculated after 5 months. The results are shown in Table 4.

[0079] The establishment method of the PDX mouse model is as follows: the lung cancer surgical tissue of the cisplatin-resistant lung cancer patient is transplanted into the severe immunodeficiency mouse (NSG) by subcutaneous transplantation, and the tumor tissue is grown in the mouse to obtain the PDX mouse model.

[0080] Table 4

[0081] Reagent Tumor shrinkage ratio, % Mouse survival rate, % 50 μM cisplatin 7.17 3.33 3.3 μM solanine 27.12 50.00 50 μM cisplatin + 3.3 μM solanine 54.25 89.33

[0082] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of solasodine to preparation of an antitumor drug sensitizer. According to the embodiment of the invention, the solamargine is used as a sensitizer of the antitumor drug for the first time, so that the drug sensitivity of tumor cells to the antitumor drug can be effectively improved, and the dosage of the antitumor drug can be reduced when the antitumor curative effect of the antitumor drug is remarkably improved. Reducing toxic and side effects of the antitumor drug on normal cells of a human body is facilitated. Therefore, according to the embodiment of the invention, the solasodine is used as the sensitizer of the antitumor drug, and has the advantages of high efficiency and low toxicity.

Description

technical field [0001] The disclosure relates to the technical field of biomedicine, specifically, the use of solanine in the preparation of antitumor drug sensitizers, a combination drug for antitumor, a medicine box product, solanine and cisplatin The use in the preparation of drugs for treating tumors and a method for detecting the sensitization effect of solanine on anti-tumor drugs. Background technique [0002] Lung cancer is a common malignant tumor in the world, and its death toll accounts for about 18.4% of all cancer deaths. At present, the clinical treatment of tumors is mainly targeted therapy, but studies have found that targeted therapy is only effective for a short period of time, after which due to the generation of chemotherapy resistance, the tumor disease is very easy to relapse. In recent years, natural medicines and traditional Chinese medicines have gradually become the first choice for anticancer drugs and tumor multidrug resistance sensitizers / revers...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/706A61K45/06C12Q1/02A61P35/00A61K33/243
CPCA61K31/706A61K45/06A61P35/00A61K33/243G01N33/5011G01N33/5044A61K2300/00
Inventor 孙志坚李程肖金平康平
Owner 北京科途医学科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap